INCY240920C62500
- 4.08
- 0.000.00%
Incyte Newsroom
Incyte Analyst Ratings
A Quick Look at Today's Ratings for Incyte(INCY.US), With a Forecast Between $64 to $92
A Quick Look at Today's Ratings for Incyte(INCY.US), With a Forecast Between $64 to $92
Incyte Analyst Ratings
TD Cowen Sticks to Its Buy Rating for Incyte (INCY)
Incyte's Promising Clinical Data Balanced With Regulatory Uncertainty: A 'Hold' Recommendation
BofA Securities Maintains Incyte(INCY.US) With Hold Rating, Raises Target Price to $66
Incyte Analyst Ratings
TD Cowen Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $80
RBC Capital Maintains Incyte(INCY.US) With Hold Rating, Maintains Target Price $67
JMP Securities Maintains Incyte(INCY.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Cochlear Limited (OtherCHEOF)
Incyte's Niktimvo Faces Market Challenges Despite FDA Approval: Analyst Upholds Hold Rating
Incyte Analyst Ratings
TD Cowen Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $80
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Incyte (INCY) and Gilead Sciences (GILD)
BMO Capital Maintains Incyte(INCY.US) With Sell Rating, Maintains Target Price $48
RBC Capital Reaffirms Their Hold Rating on Incyte (INCY)
RBC Capital Maintains Incyte(INCY.US) With Hold Rating, Raises Target Price to $67
Wells Fargo Adjusts Price Target on Incyte to $63 From $61, Maintains Equalweight Rating